gabapentin has been researched along with Drug Refractory Epilepsy in 8 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Excerpt | Relevance | Reference |
---|---|---|
"Gabapentin as monotherapy probably controlled seizures no better and no worse than comparator AEDs (lamotrigine, carbamazepine, oxcarbazepine, and topiramate)." | 9.41 | Gabapentin monotherapy for epilepsy: A review. ( Abakumova, T; Hoyle, CHV; Ziganshina, LE, 2023) |
"To evaluate the comparative safety and adjunctive efficacy of pregabalin and gabapentin in reducing seizure frequency in patients with partial-onset seizures based on prestudy modeling showing superior efficacy for pregabalin." | 9.22 | Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes. ( Almas, M; French, J; Friedman, D; Glue, P; Knapp, L; Pitman, V; Posner, HB; Yardi, N, 2016) |
"Cannabidiol and cannabidiol-enriched products have recently attracted much attention as an add-on therapy for epilepsy, especially drug-resistant seizures." | 7.91 | Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies. ( Nieoczym, D; Socała, K; Szafarz, M; Wlaź, P; Wyska, E, 2019) |
"Gabapentin as monotherapy probably controlled seizures no better and no worse than comparator AEDs (lamotrigine, carbamazepine, oxcarbazepine, and topiramate)." | 5.41 | Gabapentin monotherapy for epilepsy: A review. ( Abakumova, T; Hoyle, CHV; Ziganshina, LE, 2023) |
"To evaluate the comparative safety and adjunctive efficacy of pregabalin and gabapentin in reducing seizure frequency in patients with partial-onset seizures based on prestudy modeling showing superior efficacy for pregabalin." | 5.22 | Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes. ( Almas, M; French, J; Friedman, D; Glue, P; Knapp, L; Pitman, V; Posner, HB; Yardi, N, 2016) |
"Cannabidiol and cannabidiol-enriched products have recently attracted much attention as an add-on therapy for epilepsy, especially drug-resistant seizures." | 3.91 | Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies. ( Nieoczym, D; Socała, K; Szafarz, M; Wlaź, P; Wyska, E, 2019) |
"Gabapentin has efficacy as an add-on treatment in people with drug-resistant focal epilepsy, and seems to be fairly well-tolerated." | 2.72 | Gabapentin add-on treatment for drug-resistant focal epilepsy. ( Al-Bachari, S; Hutton, JL; Marson, AG; Panebianco, M, 2021) |
"28), indicating a dose-response relationship." | 2.61 | Pregabalin add-on for drug-resistant focal epilepsy. ( Bresnahan, R; Hemming, K; Marson, AG; Panebianco, M, 2019) |
"Gabapentin has efficacy as an add-on treatment in people with drug-resistant focal epilepsy." | 2.58 | Gabapentin add-on treatment for drug-resistant focal epilepsy. ( Al-Bachari, S; Hutton, JL; Marson, AG; Panebianco, M; Weston, J, 2018) |
"Oxcarbazepine was used in 82 patients, topiramate in 120 patients, lamotrigine in 73 patients, levetiracetam in 135 patients, pregabalin in 47 patients, tiagabine in 43 patients, gabapentin in 18 patients, lacosamide in 12 patients, and retigabine in 6 patients." | 1.48 | Comparative effectiveness of add-on therapy with newer-generation antiepileptic drugs in Bulgarian patients with refractory epilepsy. ( Viteva, E; Zahariev, Z, 2018) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 6 (75.00) | 24.3611 |
2020's | 2 (25.00) | 2.80 |
Authors | Studies |
---|---|
Ziganshina, LE | 1 |
Abakumova, T | 1 |
Hoyle, CHV | 1 |
Panebianco, M | 3 |
Al-Bachari, S | 2 |
Hutton, JL | 2 |
Marson, AG | 3 |
Viteva, E | 1 |
Zahariev, Z | 1 |
Weston, J | 1 |
Bresnahan, R | 1 |
Hemming, K | 1 |
Socała, K | 1 |
Wyska, E | 1 |
Szafarz, M | 1 |
Nieoczym, D | 1 |
Wlaź, P | 1 |
Gill, I | 1 |
Parrent, AG | 1 |
Steven, DA | 1 |
French, J | 1 |
Glue, P | 1 |
Friedman, D | 1 |
Almas, M | 1 |
Yardi, N | 1 |
Knapp, L | 1 |
Pitman, V | 1 |
Posner, HB | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Randomized, Double-blind, Parallel-group Multi-center Comparative Flexible-dose Trial Of Pregabalin Versus Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures.[NCT00537940] | Phase 4 | 482 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The seizures were recorded by the participants, by a family member, by a caregiver, or by a legal guardian and documented in a daily seizure diary. Participant's 28-day seizure frequency of all partial seizure was assessed during double blind (TP + MP) phase compared with baseline. Total partial seizure is defined as the total number of (simple partial seizure + complex partial seizure + secondary generalized tonic clonic seizure [SGTC]). (NCT00537940)
Timeframe: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks
Intervention | percent change (Median) |
---|---|
Pregabalin | -58.65 |
Gabapentin | -57.43 |
SGTC Responder is defined as a participant who shows reduction from Baseline to double-blind phase in proportion of 28-Day SGTC Seizure Rate to 28-Day All Partial Seizure Rate. (NCT00537940)
Timeframe: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks
Intervention | percentage of responders (Number) |
---|---|
Pregabalin | 30.8 |
Gabapentin | 39.8 |
Change in SGTC = (Proportion of SGTC/All Partial Seizure rate during at the double-blind phase) - (Proportion of SGTC/All Partial Seizure rate at Baseline). Negative values indicate reduction from baseline. (NCT00537940)
Timeframe: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks
Intervention | percentage of all partial seizure/28days (Mean) | |
---|---|---|
Baseline (n=114, 114) | Change from Baseline at Double Blind (n=104, 98) | |
Gabapentin | 59.60 | -2.17 |
Pregabalin | 56.53 | 1.59 |
HADS: participant rated questionnaire with 2 subscales. Hospital Anxiety and Depression Scale - anxiety (HADS-A) assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); Hospital Anxiety and Depression Scale - depression (HADS-D) assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms. (NCT00537940)
Timeframe: Baseline, Week 21
Intervention | Units on a scale (Least Squares Mean) | |||
---|---|---|---|---|
Baseline HADS-A (n=238, 240) | HADS- A Change at Week 21/ET (n=212, 210) | Baseline HADS-D (n=238, 240) | HADS-D Change at Week 21/ET (n=212, 210) | |
Gabapentin | 7.60 | -0.83 | 5.65 | -0.42 |
Pregabalin | 7.82 | -0.92 | 5.94 | -0.59 |
Participant-rated 12-item questionnaire to assess constructs of sleep over past week; 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity (range:0-24), optimal sleep (yes/no), and 9 item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except adequacy, optimal sleep and quantity, higher scores=more impairment. Scores transformed (actual raw score [RS] minus lowest possible score divided by possible RS range*100); total score range:0-100; higher score=more intensity of attribute. (NCT00537940)
Timeframe: Baseline, Week 21
Intervention | Units on a scale (Least Squares Mean) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline: Sleep Disturbance (n=238, 240) | Baseline: Snoring (n=238, 240) | Baseline: Awaken Short of Breath (n=238, 240) | Baseline: Quantity of Sleep (n=238, 240) | Baseline: Adequacy of Sleep (n=238, 240) | Baseline: Somnolence (n=238, 240) | Baseline: Sleep Problem Index (9) (n=238, 240) | Week 21: Sleep Disturbance (n=212, 210) | Week 21: Snoring (n=212, 210) | Week 21: Awaken Short of Breath (n=212, 210) | Week 21: Quantity of Sleep (n=212, 210) | Week 21: Adequacy of Sleep (n=212, 210) | Week 21: Somnolence (n=212, 210) | Week 21: Sleep Problem Index (9) (n=212, 210) | |
Gabapentin | 26.43 | 28.09 | 19.61 | 7.59 | 63.67 | 29.31 | 28.15 | 25.31 | 26.12 | 18.20 | 8.77 | 64.53 | 29.98 | 27.54 |
Pregabalin | 29.68 | 29.28 | 23.64 | 7.56 | 61.30 | 32.29 | 31.60 | 24.99 | 28.07 | 16.26 | 8.79 | 63.87 | 32.04 | 27.88 |
Participants who had at least 50% reduction in seizure frequency from Baseline to double-blind treatment (TP + MP) were considered as 50% responders. If percent change from baseline <= -50 then responder rate = 1 (yes) otherwise responder rate = 0 (no). (NCT00537940)
Timeframe: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks
Intervention | Percentage of participants (Number) | |||
---|---|---|---|---|
All Partial Seizure (n=238, 240) | Simple Partial (n=87, 88) | Complex Partial (n=161, 158) | SGTC (n=112, 114) | |
Gabapentin | 58.3 | 53.4 | 55.1 | 60.5 |
Pregabalin | 56.3 | 55.2 | 56.5 | 50.9 |
Participants who had at least 75% reduction in seizure frequency from Baseline to double-blind treatment (TP + MP) were considered as 75% responders. If percent change from baseline <= -75 then 75% responder rate = 1 (yes) otherwise responder rate = 0 (no). Total partial seizure is defined as the total number of (simple partial seizure + complex partial seizure + SGTC). (NCT00537940)
Timeframe: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks
Intervention | Percentage of participants (Number) | |||
---|---|---|---|---|
All Partial Seizure (n=238, 240) | Simple Partial (n=87, 88) | Complex Partial (n=161, 158) | SGTC (n=112, 114) | |
Gabapentin | 34.2 | 33.0 | 36.1 | 43.9 |
Pregabalin | 33.6 | 36.8 | 37.3 | 38.4 |
MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Percentage of participants with optimal sleep are reported. (NCT00537940)
Timeframe: Baseline, Week 21
Intervention | percentage of participants (Number) | |
---|---|---|
Baseline (n=238, 240) | Week 21 (n=212, 210) | |
Gabapentin | 58.8 | 58.6 |
Pregabalin | 49.2 | 51.4 |
Seizure free for 28 days was defined as participants who have not experienced any seizure (simple partial, complex partial and SGTC) for at least 28 consecutive days from their last seizure until the end of the MP. Same participant could be seizure free for a specific type of seizure but not necessarily for the other types of seizure. (NCT00537940)
Timeframe: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks
Intervention | percentage of participants (Number) | |||
---|---|---|---|---|
All Partial Seizure (n=189, 182) | Simple Partial (n=74, 66) | Complex Partial (n=126, 123) | SGTC (n=95, 91) | |
Gabapentin | 34.1 | 36.4 | 40.7 | 42.9 |
Pregabalin | 30.7 | 29.7 | 37.3 | 46.3 |
4 reviews available for gabapentin and Drug Refractory Epilepsy
Article | Year |
---|---|
Gabapentin monotherapy for epilepsy: A review.
Topics: Anticonvulsants; Carbamazepine; Drug Resistant Epilepsy; Epilepsies, Partial; Epilepsy; Gabapentin; | 2023 |
Gabapentin add-on treatment for drug-resistant focal epilepsy.
Topics: Adult; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Resistant Epilepsy; Drug Therapy, C | 2021 |
Gabapentin add-on treatment for drug-resistant focal epilepsy.
Topics: Adult; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Resistant Epilepsy; Drug Therapy, C | 2018 |
Pregabalin add-on for drug-resistant focal epilepsy.
Topics: Anticonvulsants; Drug Resistant Epilepsy; Drug Therapy, Combination; Epilepsies, Partial; Gabapentin | 2019 |
1 trial available for gabapentin and Drug Refractory Epilepsy
Article | Year |
---|---|
Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Ac | 2016 |
3 other studies available for gabapentin and Drug Refractory Epilepsy
Article | Year |
---|---|
Comparative effectiveness of add-on therapy with newer-generation antiepileptic drugs in Bulgarian patients with refractory epilepsy.
Topics: Adult; Anticonvulsants; Bulgaria; Drug Resistant Epilepsy; Drug Therapy, Combination; Female; Gabape | 2018 |
Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies.
Topics: Animals; Anticonvulsants; Brain; Cannabidiol; Chromatography, High Pressure Liquid; Disease Models, | 2019 |
Trigeminal neuropathic pain as a complication of anterior temporal lobectomy: report of 2 cases.
Topics: Amines; Analgesics; Anterior Temporal Lobectomy; Cyclohexanecarboxylic Acids; Drug Resistant Epileps | 2016 |